The annual meeting of RETIC in Cell Therapy will start today, Wednesday November 27, at the hall Auditori Joan Plaça of the UV. During two days, researchers from different groups of TerCel (RETIC of Cell Therapy) will share and discuss their investigation results about stem cells as well as their therapeutic purposes.
The key to elaborate proper strategies in what is nowadays known as regenerative medicine, in the shortest time possible, is to carry out basic and clinical research on the highest level as well as the analysis in the laboratory of ideas and hypotheses taken from treating with patients.
The Cell therapy network (TerCel), establised in 2006, is a collaborative project that started its activity under the umbrella of The Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII), to promote the investigation in cell therapy and to transfer scientific developments in the field of National Health System. It is a virtual research centre where researchers work in the institutions to which they belong while they actively participate in the agenda of cooperative investigation characteristic of a RETIC. RETICs are organisational structures that respond to the priorities of the national plan of science in health and integrate the different types of research as a strategy to shorten the interval between the production of new knowledge and its transfer and actual applicability in medical practice .
The RETIC in Cell Therapy represents a Spanish initiative for the impetus of regenerative medicine. Coordinated by the full University professor in medicine José María Moraleda (University of Murcia), This RETIC brings together some of the best groups in basic and clinical research on stem cells in the country and aims cooperative work quality that facilitates the search for effective medical solutions in cell therapy.
TerCel is organised in three research programmes that represent applications of stem cells to cardiovascular pathologies (CardioCel), musculoskeletal, immuno- hematological and metabolic diseases (OshiMeta) or nervous system diseases (NeuroCel). These programs show TerCel commitment encouraging translational research, realised with a specific purpose and it’s carried its end point, and obtaining scientific knowledge that result in improved prevention, diagnosis and treatment of health problems that are relevant to society , such as diabetes , myocardial infarction or Parkinson's disease .
TerCel also feels strongly commited to monitoring of abusive or dishonest use of stem cells for profit , through the activities of the committee of good practice and constant cooperation with the The Spanish Agency of Medicines and Medical Devices (known in Spanish as AEMPS). On the evening of Thursday 27 , as part of the activities of the meeting, a round table on "Management of fraud in cell therapy” (Manejo del fraude en la terapia celular) will be held and will feature the intervention of Sol Ruiz , Head of Division of Biotechnology and Advanced Therapies Division of Biological Products of the AEMPS.
The annual meeting of 2014 is organised by the Professor of Cell Biology at the University of Valencia Isabel Fariñas and Pilar Sepúlveda , Senior Researcher of ‘Heath Research Institute’ (Instituto de Investigación Sanitaria la Fe), both leaders of groups that are part of Tercel.
The will be opened by the principal Esteban Morcillo, the General Director of Planning , Evaluation , Research , Quality and Patient Care in the Department of Health , Teresa de Rojas, and the Assistant Director of Cell Therapy and Regenerative Medicine ISCIII , Javier Arias Díaz .
For further information: http://www.red-tercel.com/
Last update: 27 de november de 2014 08:00.
News release
